Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis
Atherosclerosis, a highly prevalent cardiovascular disease, has significantly contributed to morbidity and mortality worldwide. Despite the availability of various treatment options in clinical practice, complete reversal of the atherosclerotic pathological process remains challenging. Traditional a...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-06-01
|
| Series: | Medicine in Drug Discovery |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590098624000149 |
| _version_ | 1797202934970187776 |
|---|---|
| author | Yongfang Lin Ruibo Lin Han-Bin Lin Shiyang Shen |
| author_facet | Yongfang Lin Ruibo Lin Han-Bin Lin Shiyang Shen |
| author_sort | Yongfang Lin |
| collection | DOAJ |
| description | Atherosclerosis, a highly prevalent cardiovascular disease, has significantly contributed to morbidity and mortality worldwide. Despite the availability of various treatment options in clinical practice, complete reversal of the atherosclerotic pathological process remains challenging. Traditional anti-arteriosclerosis drugs often suffer from poor solubility, limited targeting ability and obvious adverse effects. Additionally, novel therapeutics such as genetic and protein-based drugs inherently suffer from instability issues, thereby compromising their actual curative efficacy and impeding further clinical application. Recently, nanomedicine-based drug delivery strategies have emerged as promising approaches for treating atherosclerosis due to their ability to specifically transport various drugs to target cells, microstructures and specific molecules within lesion sites. These advanced features enhance drug properties and bioavailability while minimizing off-target effects. Moreover, numerous studies have demonstrated that nanomedicine not only inhibits plaque progression but also reduces lesional areas and eventually reverses atherosclerosis. The utilization of nanomedicine is considered an important therapeutic tactic for further mitigating residual risks associated with atherosclerosis. This review provides a comprehensive overview of emerging nanomedicine-based strategies for targeted delivery of anti-atherosclerosis drugs, elucidating their distinct mechanisms and highlighting their remarkable efficacy in combating atherosclerosis. Additionally, critical challenges and future perspectives associated with the development and application of anti-arteriosclerosis nanomedicine are thoroughly discussed. |
| first_indexed | 2024-04-24T08:11:20Z |
| format | Article |
| id | doaj.art-28e6e9d3f19e4744a49f71bcf47f5852 |
| institution | Directory Open Access Journal |
| issn | 2590-0986 |
| language | English |
| last_indexed | 2024-04-24T08:11:20Z |
| publishDate | 2024-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Medicine in Drug Discovery |
| spelling | doaj.art-28e6e9d3f19e4744a49f71bcf47f58522024-04-17T04:49:49ZengElsevierMedicine in Drug Discovery2590-09862024-06-0122100189Nanomedicine-based drug delivery strategies for the treatment of atherosclerosisYongfang Lin0Ruibo Lin1Han-Bin Lin2Shiyang Shen3Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; University of Chinese Academy of Sciences, Beijing 100049, ChinaZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; Guangzhou University of Chinese Medicine, Guangzhou 510006, ChinaZhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Corresponding authors at: Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China; Pharmaceutical Preparation Research Center, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China; University of Chinese Academy of Sciences, Beijing 100049, China; Corresponding authors at: Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan 528400, China.Atherosclerosis, a highly prevalent cardiovascular disease, has significantly contributed to morbidity and mortality worldwide. Despite the availability of various treatment options in clinical practice, complete reversal of the atherosclerotic pathological process remains challenging. Traditional anti-arteriosclerosis drugs often suffer from poor solubility, limited targeting ability and obvious adverse effects. Additionally, novel therapeutics such as genetic and protein-based drugs inherently suffer from instability issues, thereby compromising their actual curative efficacy and impeding further clinical application. Recently, nanomedicine-based drug delivery strategies have emerged as promising approaches for treating atherosclerosis due to their ability to specifically transport various drugs to target cells, microstructures and specific molecules within lesion sites. These advanced features enhance drug properties and bioavailability while minimizing off-target effects. Moreover, numerous studies have demonstrated that nanomedicine not only inhibits plaque progression but also reduces lesional areas and eventually reverses atherosclerosis. The utilization of nanomedicine is considered an important therapeutic tactic for further mitigating residual risks associated with atherosclerosis. This review provides a comprehensive overview of emerging nanomedicine-based strategies for targeted delivery of anti-atherosclerosis drugs, elucidating their distinct mechanisms and highlighting their remarkable efficacy in combating atherosclerosis. Additionally, critical challenges and future perspectives associated with the development and application of anti-arteriosclerosis nanomedicine are thoroughly discussed.http://www.sciencedirect.com/science/article/pii/S2590098624000149NanomedicineDrug carrierDrug deliveryAtherosclerosis treatmentTargeted strategy |
| spellingShingle | Yongfang Lin Ruibo Lin Han-Bin Lin Shiyang Shen Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis Medicine in Drug Discovery Nanomedicine Drug carrier Drug delivery Atherosclerosis treatment Targeted strategy |
| title | Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis |
| title_full | Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis |
| title_fullStr | Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis |
| title_full_unstemmed | Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis |
| title_short | Nanomedicine-based drug delivery strategies for the treatment of atherosclerosis |
| title_sort | nanomedicine based drug delivery strategies for the treatment of atherosclerosis |
| topic | Nanomedicine Drug carrier Drug delivery Atherosclerosis treatment Targeted strategy |
| url | http://www.sciencedirect.com/science/article/pii/S2590098624000149 |
| work_keys_str_mv | AT yongfanglin nanomedicinebaseddrugdeliverystrategiesforthetreatmentofatherosclerosis AT ruibolin nanomedicinebaseddrugdeliverystrategiesforthetreatmentofatherosclerosis AT hanbinlin nanomedicinebaseddrugdeliverystrategiesforthetreatmentofatherosclerosis AT shiyangshen nanomedicinebaseddrugdeliverystrategiesforthetreatmentofatherosclerosis |